17,807 Shares in TG Therapeutics, Inc. $TGTX Acquired by PSP Research LLC

PSP Research LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 17,807 shares of the biopharmaceutical company’s stock, valued at approximately $531,000.

Several other large investors have also recently added to or reduced their stakes in the business. Amalgamated Bank increased its stake in TG Therapeutics by 1.1% during the 3rd quarter. Amalgamated Bank now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,418,000 after buying an additional 424 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in TG Therapeutics by 1.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after buying an additional 441 shares during the period. Smartleaf Asset Management LLC increased its stake in TG Therapeutics by 21.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 467 shares during the period. Bessemer Group Inc. increased its stake in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 486 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its stake in TG Therapeutics by 1.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,062 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 500 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TGTX. Zacks Research downgraded shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, May 1st. JPMorgan Chase & Co. dropped their price objective on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. HC Wainwright increased their price objective on shares of TG Therapeutics from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.50.

TG Therapeutics Trading Down 0.1%

NASDAQ TGTX opened at $39.43 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. The firm’s fifty day moving average price is $34.60 and its 200 day moving average price is $32.00. The company has a market capitalization of $6.04 billion, a price-to-earnings ratio of 13.79 and a beta of 1.68. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $44.65.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The company’s quarterly revenue was up 69.5% on a year-over-year basis. During the same period last year, the business earned $0.03 earnings per share. On average, sell-side analysts expect that TG Therapeutics, Inc. will post 1.31 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.